A study by Bate‐Eya et al.233has demonstrated that combination treatment with an MCL‐1 inhibitor (1210477) and ABT199 leads to significant synergistic effects against NB cells. The above findings indicate that the use of combinations of targeted therapy may be necessary to overcome the resistance, including amyloid cell leukemia sequence MCL‐1‐dependent resistance, to Bcl‐2 and other targeted inhibitors. The gene discussed is MCL1; the disease is neuroblastoma.